AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06418737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep HygieneTraining
Description: Training Content~* Importance of Sleep: The vital importance of sleep for physical and mental health.~* Benefits of Adequate and Quality Sleep: The numerous benefits of sufficient and good quality sleep.~* Sleep Stages: The different stages of sleep and their characteristics.~* Sleep Hygiene: The concept of sleep hygiene and its importance for improving sleep quality.~* What to Do?~* What to Avoid for Better Sleep?
Study NCT04873440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manganese Chloride
Description: Administered by inhalation at 0.4mg/kg/d twice a week
Study NCT06184542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTacP (three-dose primary vaccination)
Description: Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on the M3-M4-M5, M2-M3-M4, or M2-M4-M6 immunization schedule
Study NCT06184542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DT (one-dose booster)
Description: Diphtheria-Tetanus Combined Vaccine of 0.5mL on Day 0
Study NCT04873440 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Measurable lesions were targeted for radiotherapy at the discretion of the treating physician.Standard-of-care radiotherapy or SBRT were both allowed.
Study NCT04873440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy
Description: The same chemotherapy and/or anti-PD-1 therapy before thei patients' enrolment were allowed. Whether and which should be given depends on the treatment regimen before enrollment.
Study NCT06184542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP (one-dose booster)
Description: Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on Day 0
Study NCT04703192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat Tosylate
Description: Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
Study NCT06184542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PENTAXIM (one-dose booster)
Description: Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on Day 0
Study NCT06184542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP (three-dose primary vaccination)
Description: Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on an M3-M4-M5immunization schedule
Study NCT05356988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity experiment
Description: The Physical Activity (PA) group will have access for one year to the PA website to help increase aerobic and strength training activities.
Study NCT05356988 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and flexibility control
Description: The static Balance and Flexibility (BF) website will include infographics, videos, and articles for participants to view at their leisure around stretching and balance exercises.
Study NCT06133556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCBC regimen
Description: using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
Study NCT06133556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bu/Cy regimen
Description: control group, the standard conditioning regimen Busulfan/Cyclophosphamide
Study NCT06184542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PENTAXIM (three-dose primary vaccination)
Description: Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on the M3-M4-M5 or M2-M3-M4 immunization schedule
Study NCT05604573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cell free DNA in blood, genetic mutation in tissue
Description: Diagnostic test for cell free DNA in blood, genetic mutation in tissue
Study NCT05145699 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VR-based post-stroke hemineglect evaluation system
Description: Evaluation system applied with virtual environment using Pico Neo 2 eye
Study NCT05145699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-based post-stroke hemineglect evaluation system
Description: Evaluation system applied with virtual environment using Pico Neo 2 eye
Study NCT05145699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR-based post-stroke hemineglect evaluation system
Description: Evaluation system applied with virtual environment using Pico Neo 2 eye
Study NCT05016024 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Colilen IBS
Description: Patients will take Colilen IBS in First or Second Period
Study NCT05016024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Patients will take PlaceboS in First or Second Period
Study NCT05671523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Firstly the skin is cleaned with a piece of cotton immersed in alcohol. Then sterilized disposable thin, stainless steel needles (25 × 0.30 mm) will be inserted into the skin over the nodule in A1 pulley anatomic location. The duration of needling will be 1 minute. The needle will be inserted deeply at 45° to the level of metacarpophalangeal level to the nodule. The needle may be inserted into the tendon. This is confirmed by needle movement when the patient ﬂexes and extends the distal phalanx. The needle is withdrawn slowly until this motion ceases, and the needle tip is in the A1 pulley. This will be repeated 2 times per week for 5 weeks.
Study NCT05671523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: Finger splint is designed to stabilize and immobilize a small finger joint. A wide, flat band offers comfortable pressure distribution and control. Contoured finger splint with a comfortable, close fit. The patient will use the splint at night. Can easily be adjusted to accommodate swollen digits. Suitable for a number of finger conditions.~Therapeutic ultrasound is often used by physiotherapists to reduce pain, increase circulation and increase mobility of soft tissues. Additionally, the application of ultrasound can be helpful in the reduction of inflammation, reducing pain and the healing.
Study NCT05671523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Finger splint is designed to stabilize and immobilize a small finger joint. A wide, flat band offers comfortable pressure distribution and control. Contoured finger splint with a comfortable, close fit. The patient will use the splint at night. Can easily be adjusted to accommodate swollen digits. Suitable for a number of finger conditions.~Therapeutic ultrasound is often used by physiotherapists to reduce pain, increase circulation and increase mobility of soft tissues. Additionally, the application of ultrasound can be helpful in the reduction of inflammation, reducing pain and the healing.
Study NCT04724512 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: suture
Description: a type of suture used in entropion surgery
Study NCT04866095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiogram
Description: Transthoracic echocardiogram (TTE) is a widely used and validated imaging technique which involves the study of the heart and great vessels through multiple examination windows. In particular, the subcostal window represents the gold standard for evaluating the diameter of the inferior vena cava (IVC) and its compliance, allowing the physician to obtain valuable information on the volume status of patients. Acquiring images in the subcostal window with a transthoracic echocardiogram (TTE) can be, in some cases, difficult or impossible due to the presence of drainages or surgical wounds: in such cases an alternative could be represented by the trans-hepatic window. This has not been validated in the scientific litterature.
Study NCT04866095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Sight system
Description: The Clear Sight System is a non-invasive blood pressure (BP) monitoring system, where the CO is determined analysing the photo-plethysmography curve by a miniaturized pressure cuff and infrared LEDs.~Its main advantage is to assess CO continuously in a completely non-invasive way, following its variations and thereby contributing to the detection of hypovolaemia. Other visualized parameters are: the stroke volume (SV), the systemic vascular resistance (SVR) as well as the BP and the heart rate (HR).
Study NCT05426018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SY-009 capsules
Description: 3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
Study NCT05426018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-009 capsules
Description: 3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
Study NCT06351982 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electro Medical Systems AIRFLOW® Prophylaxis Master Device
Description: 1. Disclosure of biofilm with erythrosine,~2. Removal of supragingival and subgingival (up to 4 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS- Dental, Nyon Switzerland).~3. Supra- and sub- gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology.
Study NCT06351982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand and ultrasonic scalers and curettes
Description: Combination of ultrasonic and hand instrumentation only. Pockets ≥4 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
Study NCT05242341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: application(APP) teaching
Description: Teaching the use of the APP
Study NCT04798846 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dorsal plating
Description: Spanning Plate inserted dorsally below tendons Spanning External Fixator by rods inserted in distal radius and metacarpals
Study NCT06138938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative abdominal irrigation
Description: All blood clots and other remnants were manually externalized with a sponge holder forceps from the pelvic areas following the uterine incision closure. Then, 1,000 mL of warm saline irrigation was poured into the vesicouterine cavity and aspirated as much as possible in the reverse Trendelenburg position using an aspirator, carefully avoiding any contact with the intestines.
Study NCT06344871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroLF
Description: NeuroLF Scan
Study NCT06344871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PET scan
Description: Scan on conventional PET system
Study NCT06174961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: 15,000 units of unfractionated heparin administered in the thigh
Study NCT06174961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double-legged cycle ergometer exercise
Description: One hour of double-leg cycle ergometer exercise
Study NCT06174961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-legged cycle ergometer exercise, with unfractionated heparin injection in the exercising leg
Description: One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
Study NCT06174961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-legged cycle ergometer exercise, with unfractionated heparin injection in the non-exercising leg
Description: One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
Study NCT06174961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No exercise
Description: No exercise
Study NCT05818384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wakaya: Rising Up for Choctaw Youth Curriculum
Description: An experiential, outdoor, nature-based program grounded in Choctaw values. It is a multi-level intervention that increases individual motivation and leadership skills to make healthy behavioral choices for behavior and exercise.
Study NCT05245994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib
Description: Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy. Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator. The initial dose of olaparib is 300mg twice daily. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food.
Study NCT00964951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.
Study NCT00964951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
Study NCT04901663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG
Description: Orally twice daily for 2 weeks
Study NCT04901663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 MG; Amoxicillin 1000 MG
Description: Orally twice daily for 2 weeks
Study NCT04918381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellFX System
Description: Nano-Pulse Stimulation (NPS)
Study NCT01489501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical transplantation of CAOMECS to the ocular surface
Description: Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
Study NCT05659914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib+durvalumab
Description: olaparib: 300 mg tablets taken orally twice daily and durvalumab: 1500 mg via IV infusion q4w
Study NCT04234347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous access method
Description: Comparing long and short axis approach to USGPIV access.
Study NCT05695040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary workshop proteins
Description: The workshop will have 2 objectives:~* Information of the importance of protein after bariatric surgery and the different sources of protein in the diet.~* Manipulation of a tool in the form of a real size and shape stomach (before and after surgery) that patients will be able to fill and manipulate in order to visualize the quantities needed to achieve the sensation of satiety.
Study NCT04104854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug coated balloon
Description: Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for >30 seconds
Study NCT05934240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy group
Description: Manual therapy will be applied to the diaphragm and thoracic region.
Study NCT05934240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham-manual therapy
Description: Sham-manual therapy will be applied to the diaphragm and thoracic region.
Study NCT05808673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Post-change CMAB807X
Description: for subcutaneous injection only
Study NCT05808673 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pre-change CMAB807X
Description: for subcutaneous injection only
Study NCT05808673 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva®
Description: for subcutaneous injection only
Study NCT06182176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine and Amodiaquine
Description: The intervention drugs are standard drugs approved by the World Health Organisation for the preventive treatment of malaria (sulphadoxine-pyrimethamine and amodiaquine), schistosomiasis (praziquantel) and soil-transmitted helminths (albendazole).
Study NCT06182176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine and Amodiaquine
Description: The intervention drugs are standard drugs approved by the World Health Organisation for the preventive treatment of malaria (sulphadoxine-pyrimethamine and amodiaquine), schistosomiasis (praziquantel) and soil-transmitted helminths (albendazole).
Study NCT05340348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples (36 mL) + fecal samples + hair sample
Description: Blood samples at inclusion, 2 years later and/or if relapse, fecal samples at inclusion and every years for 5 years, hair sample at inclusion
Study NCT06005350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen
Description: Nicotinamide-Riboside-Chloride Preparation 1000mg/day
Study NCT06005350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Preperation
Study NCT06297577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Albumin Platelet Rich Fibrin (Alb-PRF) combined with minimally invasive surgical technique (MIST)
Description: Albumin-PRF will be placed into intrabony defect
Study NCT05722366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active video game
Description: With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
Study NCT05722366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
Study NCT04754269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage Intervention
Description: Parents will watch a video that promotes optimal beverage practices for young children including discouraging consumption of sugar-sweetened beverages and fruit juice and encouraging consumption of water and unsweetened milk. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
Study NCT04754269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Intervention
Description: Parents will watch a video that promotes reading to children and includes specific ideas and techniques for how to make reading interactive and engaging. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
Study NCT05252286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video watching
Description: Watching video In this group, when the patient conducts their rehabilitation exercise, the therapist would record the poor physical movement pattern from his/her performance by using the mobile phone or tablet. The patients will be provided with watching video exercise, containing 3-5 items of their poor physical performance, selected by the therapist as a feedback to let the patient practice when they return their bedside ward after their rehabilitation time. The content of video-watching exercise program will be changed or modified once weekly as the patient improve the physical movement performance.
Study NCT05252286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper group
Description: In the paper sheet group, the therapist will give three to five poor movement patterns, selected from the patient conducting their rehabilitation program, to practice when returning bedside ward.
Study NCT05252286 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral education group
Description: the patient only receives the oral exercise education about how to improve their physical performance during their hospital stay.
Study NCT06297577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surgical technique (MIST)
Description: MIST will be the surgical access for treatment of Intrabony defect
Study NCT06363695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare Kenya
Description: Adapted from SafeCare, this is a strengths-based program for parents with children ages 18 months through age 5, teaching parents skills and knowledge in three areas: 1) parent-child interactions, 2) child health, and 3) home safety.